NBP NovaBridge Biosciences
Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 · USD | 2025Q3*2025-09-30 · USD | 2024Q4*2024-12-31 · USD | 2024Q3*2024-09-30 · USD | 2020Q4*2020-12-31 · CNY | 2019Q4*2019-12-31 · CNY |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | 0 |
| R&D expense | $55.66M | $3.18M | $6.03M | $4.47M | 286.23M | 262.04M |
| SG&A expense | $17.24M | $5.81M | $7.34M | $7.94M | 91.63M | 71.82M |
| Operating income | -$72.90M | -$8.99M | -$13.37M | -$12.41M | — | — |
| Interest expense | — | — | — | — | 0 | 525,000 |
| Pretax income | -$72.86M | -$6.83M | -$10.84M | -$20.49M | 1.05B | -348.57M |
| Income tax | $0 | $0 | $0 | $0 | 12.23M | — |
| Net income | -$30.79M | -$6.83M | -$10.84M | -$20.49M | 1.04B | -348.57M |
| EBITDA | -$72.89M | -$8.97M | -$13.31M | -$12.39M | — | — |
| EPS (diluted) | — | — | — | — | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $210.63M | $228.06M | $68.26M | $79.33M | 4.76B | 1.19B |
| Short-term investments | $210,000 | $210,000 | $105.14M | — | 31.53M | 32.00M |
| Receivables | — | — | — | — | 130.50M | — |
| Inventory | — | — | — | — | 0 | — |
| Current assets | $217.52M | $232.78M | $176.69M | — | 5.34B | 1.36B |
| PP&E, net | $140,000 | $155,000 | $201,000 | — | 25.27M | 30.07M |
| Goodwill | — | — | — | — | 162.57M | 162.57M |
| Intangibles | — | — | — | — | 120.44M | 148.84M |
| Total assets | $260.52M | $277.41M | $212.68M | — | 6.33B | 1.74B |
| Current liabilities | $26.89M | $16.09M | $8.45M | — | 576.12M | 588.48M |
| Short-term debt | — | — | — | — | — | 50.00M |
| Total liabilities | $29.58M | $18.50M | $11.52M | — | 706.65M | 668.09M |
| Shareholders' equity | $230.94M | $258.92M | $201.16M | $219.74M | 5.63B | -2.03B |
| Shares outstanding | 265.38M | 265.17M | 187.45M | — | 164.89M | 8.36M |
| Cash flow statement | ||||||
| Operating cash flow | -$14.60M | $1.84M | -$10.95M | $8.42M | 1.02B | -215.99M |
| Capital expenditure | $0 | $0 | $38,000 | $1,000 | 3.25M | 7.62M |
| Free cash flow | -$14.60M | $1.84M | -$10.99M | $8.42M | 1.01B | -223.61M |
| Investing cash flow | $0 | $0 | -$109,000 | -$81.66M | 54.48M | 77.33M |
| Financing cash flow | -$3.02M | — | $0 | $0 | 844.79M | 113.30M |
| Depreciation & amortization | $15,000 | $17,000 | $61,000 | $20,000 | 5.00M | 3.00M |
| Stock-based compensation | $3.94M | $1.46M | $824,000 | $318,000 | 100.89M | 10,000 |
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.